ArticleSurgical case reports2025
Surgery for Aspergillus Empyema with Refractory Pleural Fistula Following COVID-19 Pneumonia after Temporizing Measure Using Endobronchial Watanabe Spigot: A Case Report.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionApproximately 20% of patients who contract coronavirus disease (COVID-19) pneumonia require oxygen therapy; of these patients, approximately 5% progress to acute respiratory distress syndrome, necessitating mechanical ventilation. The incidence of secondary infections among patients with COVID-19 is relatively low (16% for bacterial infections and 6.3% for fungal infections), but is predominantly observed in those with severe respiratory failure. Microvascular damage in COVID-19 can also lead to thrombus formation, causing infarctions, and in some cases, necrotizing pneumonia with cavity formation. Pulmonary resection may be necessary in patients who develop pneumothorax or empyema. Management options in complicated COVID-19 continue to evolve and should be individualized. Here, we present a case of Aspergillus empyema with refractory pleural fistula following COVID-19 pneumonia. CASE PRESENTATION: The patient was hospitalized in the intensive care unit for respiratory failure caused by COVID-19 pneumonia and developed a right pneumothorax 1 month after admission, with a halo sign in the middle lobe on computed tomography. Persistent massive air leakage and hypoxia developed, even with mechanical ventilation. Initially, to reduce the massive air leakage, endobronchial silicone spigot (endobronchial Watanabe spigot: EWS) were placed in the right B2 and middle lobe bronchi to stabilize the severe respiratory failure and septic shock. After EWS placement, the air leak decreased, with gradual improvement in the patient's multi-organ failure status. Subsequently, the patient underwent a right middle lobectomy and upper lobe wedge resection. Histopathology confirmed an active Aspergillus infection in the resected lung, and voriconazole was administered postoperatively. Air leakage persisted postoperatively, necessitating repeat surgery and, finally, thoracoplasty and negative pressure wound therapy. The patient was eventually discharged with home oxygen therapy.
conclusionsThis case illustrates the successful treatment of invasive pulmonary aspergillosis with refractory pulmonary fistula and empyema following COVID-19 pneumonia using a combination of endoscopic and surgical interventions. In cases of severe COVID-19 pneumonia, clinicians must remain vigilant for secondary infections, including aspergillosis. EWS placement can be effective in reducing significant air leakage and stabilizing patients' condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.